Salman Bhai

Clinical Development Lead at Taysha Gene Therapies

Salman Bhai's work experience is as follows:

- Current: Director of the Neuromuscular Disease Center at Texas Health Resources since February 2021.

- Current: Clinical Development Lead at Taysha Gene Therapies since September 2021. In this role, Salman leads the clinical development efforts for GAN and has previously contributed to genetic testing strategies, patient identification through machine learning, and vendor relationship management within the Global Medical Affairs team.

- Assistant Professor of Neurology at UT Southwestern Medical Center since August 2020. In addition to providing clinical expertise in neurology and neuromuscular disorders, Salman is also the Principal Investigator at the Neuromuscular Lab, where they conduct research on inflammatory and metabolic muscle diseases through multi-omics analysis and immune phenotyping. Salman has also served as a Site Principal Investigator for clinical trials.

- Former roles at Mass General Brigham include being a Neuromuscular Fellow from July 2019 to June 2020 and a Neurology Resident from July 2016 to June 2019.

- Translational Medicine Consultant at Relay Therapeutics from August 2019 to October 2019.

- Internal Medicine Intern at Brigham and Women's Hospital from July 2015 to June 2016.

- Clinical trial co-investigator at the Massachusetts General Hospital, Division of Wilderness Medicine from March 2015 to May 2015.

- Researcher at the Harvard Stem Cell Institute from October 2013 to August 2014.

Salman Bhai completed their education with a Bachelor of Science (BS) degree in Mathematics from Duke University, where they studied from 2006 to 2010. Later, they pursued further studies at Harvard Medical School, earning a Doctor of Medicine (M.D.) degree between 2010 and 2015. No specific field of study is mentioned for their medical degree.

Links

Previous companies

Mass General Brigham logo
Massachusetts General Hospital logo

Timeline

  • Clinical Development Lead

    September, 2021 - present

View in org chart